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Abstract 
Purpose: To determine the susceptibilities of fluconazole and voriconazole based on slime production 
by Candida spp.   
Methods: Candida strains (115) isolated in the period between January 2011 and January 2012 were 
included in this study. Conventional methods were used for the identification. Candida albicans and 
non-C. albicans isolates were tested for slime production with modified tube adherence test and 
antifungal resistance with disk diffusion method.  
Results: Slime positivity was 31.3 % in all Candida species. Slime positivity in non-C.albicans isolates 
(44.89 %) was higher than in C. albicans species (21.21 %).  All C. albicans isolates were sensitive to 
fluconazole and voriconazole. The highest resistance to fluconazole (40 %) and voriconazole (5%) was 
by C. glabrata strains.  
Conclusion: Species definition and determination of antifungal susceptibility patterns are advised for 
the proper management and treatment of patients. 
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Candida spp. are members of normal flora and 
are also oppurtunistic pathogens that can cause 
serious systemic infections especially in 
immuncompromised patients. Candida infections 
have increased in the last two decades because 
of immunosuppresive treatments, long-term 
catheterisation, prolonged use of broad-spectrum 
antibiotics,cancer treatments and HIV infections. 
Various factors play a role in the pathogenesis of 
Candida infections, and slime production in 
Candida species is an important virulance factor 
which is associated with adherence to the 
surface of catheters and biomedical devices, and 
thus protects microorganisms from host 
defences. Slime (biofilm)-producing Candida 
species are known to be more resistant to 
immune response and antifungal agents which 
leads to treatment failure [1,2]. 
 
The aim of this study was to determine the 
relationship between slime production by 
Candida spp and susceptibility to fluconazole 
and voriconazole. 
 
Kaskatepe & Yildiz 







Sabouraud dextrose agar (SDA, Merck), Brain 
Heart Infision Broth (Plasmatec), Safranin 




A total of 115 Candida species, isolated from 
various clinical samples in the Clinical 
Microbiology Laboratory of Ankara Dışkapı 
Yıldırım Beyazıt Training Hospital, were included 
in this study. Candida species isolated from the 
same patient were excluded. Prior to being 
tested, all strains were subcultured twice on 
Sabouraud dextrose agar (SDA) to ensure 
viability and purity. For the identification of the 
isolates, conventional methods were used such 
as germ tube formation, microscopic morphology 
on cornmeal-Tween 80 Agar as well as 
commercial methods such as CHROMagar 
Candida. Candida dubliniensis isolates were 
identified on the basis of their initial dark green 
colony color on CHROMagar. If the species 
couldn’t be identified by these methods they 
were classified as Candida spp.  C.albicans 
ATCC 10231,reference strain was also included 




Slime production was determined using a 
modified tube adherence test. A loopful of 
organisms from the surface of a Sabouraud 
dextrose agar plate was inoculated into a 
polystyrene falcon tube containing 10 ml of 
Sabouraud broth supplemented with glucose 
(final concentration, 8%). The tubes were 
incubated at 35 °C for 24 h. The cell suspension 
in the tubes were poured out and washed with 
distilled water two times. After dying, 1 % 
safranine, the tubes were examined for the 
presence of the viscid slime layer. Slime 
production by each isolate was scored as 
negative, weak positive (1+), moderate positive 
(2+ or 3+) and strong positive(4+). Each isolate 
was tested at least three times and each tube 
was scored independently by two observers.  
 
Antifungal agents and susceptibility test 
 
Fluconazole (25 µg, Oxoid) and voriconazole (1 
µg, Oxoid) disks were used for antifungal 
susceptibility tests. Antifungal susceptibility 
testing of Candida strains was performed 
according to the guidelines and criteria of Clinical 
and Laboratory Standards Institute (CLSI/M44-A) 
using disk diffusion method [3]. Inoculum was 
prepared from 24 h cultures in SDA. Plates 
containing Mueller-Hinton agar supplemented 
with 2 % glucose and 0.5 µg/ml methylene blue 
at a depth of 4.0 mm were used. The agar 
surface was inoculated by using a swab dipped 
in a cell suspension adjusted to the turbidity of a 
0.5 McFarland standard. Fluconazole and 
voriconazole disks were placed on the surfaces 
of the plates. After incubation at 35 °C for 24 h, 
the inhibition diameters around the disks were 
measured.  
 
The interpretive criteria for the fluconazole and 
voriconazole disk diffusion tests were those of 
the CLSI: susceptible(S), zone diameters of ≥ 19 
mm fluconazole and ≥ 17 mm voriconazole; 
intermedier (I) zone diameters of 15 to 18 mm 
fluconazole and 14 to 16 voriconazole;  and 
resistant (R), zone diameters of ≤ 14 mm 




The data were analyzed using SPSS program, 
version 17.0 and subjected to Chi-square test. At 
95% confidence interval, P < 0.05 was 




Slime activity and antifungal susceptibility of 115 
Candida strains isolated from clinical samples 
were investigated in this study. The most 
common species recovered were C. albicans 
(57.4 %) followed by C. glabrata (17.4 %), 
C.tropicalis (12.2 %), C. parapsilosis (5.21 %), C. 
dubliniensis (5.21 %) and Candida spp. (2.60 %) 
A total of 36 (31.3 %) out of 115 Candida isolates 
were slime producers. The highest slime 
production was found among C. parapsilosis 
isolates  (66.66 %). It  was also shown that non-
C. albicans strains (44.89 %) produced 
significantly higher slime factor than C. albicans 
strains (21.21 %) (p = 0.007). Slime production 
results are reported in Table 1. 
 
A total of eight C.glabrata isolates were resistant 
to fluconazole and one C.glabrata isolate was 
intermedier (I) to this antifungal. All Candida 
isolates were susceptible to voriconazole except 
one resistant and one intermedier C. glabrata 
isolates. These isolates were also resistant to 
fluconazole. Antifungal susceptibility data are 
listed in Table 2. 
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   Table 1: Slime production by Candida isolates 
 







C. albicans (66) 52 5 1 8 14 
C. glabrata (20) 15 4 1 - 5 
C. tropicalis (14) 5 - 1 8 9 
C. parapsilosis (6) 2 - - 4 4 
C. dubliniensis (6) 4 - 2 - 2 
Candida spp.(3) 1 - 1 1 2 
Total non-C.albicans (49) 27 4 5 13 22 
 Table 2: Antifungal susceptibility of Candida spp. 
 
S  n(%) I  n(%) R  n(%) Species 
Flu Vor Flu Vor Flu Vor 
C. albicans 66 (100) 66 (100) - - - - 
C. glabrata  11 (55) 18 (90) 1 (5) 1 (5) 8 (40) 1 (5) 
C. tropicalis 14 (100) 14 (100) - - - - 
C. parapsilosis 6 (100) 6 (100) - - - - 
C. dubliniensis 3 (50) 6(100) 3 (50) - - - 
Non-C. albicans 37 (75.5) 47 (96) 4 (8.2) 1 (2) 8 (16.3) 1 (2) 
Candida spp. 3 (100) 3 (100) - - - - 
Total 103(89.6) 113 (98.2) 4 (3.4) 1 (0.9) 8 (7) 1(0.9) 
  
We investigated the correlation between slime 
activity and antifungal susceptibility of the two 
antifungal agents. For all Candida species no 
correlation was detected between slime and 




Candida spp. can cause both superficial and 
serious systemic diseases and are now 
recognized as one of the major agents of 
nosocomial infections. Recent data from the US 
National Nosocomial Infections Surveillance 
System [1] rank these organisms as the fourth 
most common cause of bloodstream infection. 
Biofilms are the structured microbial communities 
that are attached and encased in the matrix of 
exopolimeric material and are important for the 
development of clinical infection. Many candida 
infections involve the formation of biofilms on 
implanted devices. When bacteria exist in the 
biofilm form they are 10 - 1000 times more 
resistant to antibiotics than are planktonic cells 
[1,4]. In the present study, we investigated the 
correlation between slime production and 
resistance to two antifungal agents.  
 
Various rates of slime production have been 
reported in a number of studies.  While 
Mohandas and Ballal reported high rates of 51  
and 90.32 % in 2011 for C. albicans and non-C. 
albicans isolates, respectively [5], in other 
studies which were supported by our results as 
well, lower resistance rates were found [6,7]. In 
this study  total slime positivity rate was 31.31 % 
(21.21 % in C. albicans and 44.89 % in non-C. 
albicans isolates). 
 
Similarly to our results, more recent studies 
showed slime production is common especially in 
non-C. albicans strains. In Tumbarello et. al 
study, they reported 22.6% slime positivity rate in 
C. albicans and 33.3% in non-C. albicans 
isolates [6]. Yıldırım et. al found 17% in C. 
albicans, 33% in non- C. albicans [7]. In contrast 
to this findings, Dag et al found slime positivity 
39.3 and 37.7 % in C. albicans and non-C. 
albicans, respectively [8]. We found that there 
was a statistically significantly higher slime 
production in non-C. albicans strains than in C. 
albicans isolates. The highest slime production 
was found in C. tropicalis among all non-C. 
albicans isolates including C. glabrata, C. 
parapsilosis, C. dubliniensis.  
 
Despite the widespread use of fluconazole for 
more than two decades, we found no evidence 
that C. albicans has developed increased 
resistance to fluconazole. All C. albicans species 
were sensitive to both antifungal agents. 
However, resistance rates to fluconazole in C. 
albicans are different in the other studies [9-11]. 
It is known that non-C. albicans species increase 
in candida infections and these species have a 
resistance to antifungal drugs. Non-C. albicans 
species have various degrees of susceptibility to 
the frequently used antifungal drugs while C. 
krusei is intrinsically resistant to fluconazole, C. 
glabrata is less susceptible or has higher minimal 
inhibitory concentrations (MICs) than other 
Candida species [9] C. glabrata is an 
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oppurtunistic pathogen that has become 
increasingly frequent in bloodstream and 
mucosal infections in immunocompromised 
patients .The increasing use of azole antifungals 
for the treatment of C. glabrata infections has 
resulted in emergence of resistance strains [11]. 
In the present study, there was a statistically 
significant higher fluconazole resistance in non-
C. albicans than C. albicans isolates (p = 0.005). 
Resistance to fluconazole was observed 
relatively high, mainly in isolates of C. glabrata. 
Eight (40 %) C. glabrata isolates were found 
resistant to fluconazole and one C. glabrata was 
found intermedier. The resistance rates for 
fluconazole in C. glabrata are varried in the other 
studies.   
 
All Candida spp. were susceptible to 
voriconazole except one C. glabrata strain which 
was also resistant to fluconazole. In addition, one 
C. glabrata isolate was found intermedier and it 
was also resistance to fluconozole too. Cross 
resistance between fluconazole and voriconazole 
is described among isolates of C.glabrata. The 
results of our antifungal susceptibility test are 
generally consistent with the findings from other 
studies. Similarly in Gültekin et al’s study 
conducted with 46 Candida spp isolated from 
blood samples, all Candida isolates were 
determined to susceptible to fluconazole and 
voriconazole [12]. However, rates of resistance 
tofluconazole (5 %) and voriconazole (7.7 %) 
have been reported for C. albicans isolates [10].  
 
In the present study which was conducted with 
66 C. albicans and 49 non-C. albicans strains, 
we investigated the association between slime 
activity and susceptibility to fluconazole and 
variconazole. The results showed that some 
Candida species produced slime but the 
antifungal susceptibility test performed indicate 
that some of these species were susceptible to 
fluconazole and voriconazole. For C. albicans 
and non-C. albicans, no correlation was detected 
between slime activity and the susceptibility of 
the two antifungal agents because all C. 
albicans, C. tropicalis and C. parapsilosis  strains 
were sensitive to both antifungal agents. Similar 
results have been found in other studies In one 
of them, conducted with 19 C. parapsilosis and 
35 C. albicans strains, the authors investigated 
whether slime activity patterns correlated with the 
strains’ susceptibility to fluconazole, ketoco-
nazole and amphothericine B. They did not find 
correlation between slime activity and the MIC of 
all three antifungal agents [13]. Also, Shin et al 
did not find any significant association between 
biofilm production and clinical characteristics of 
candidemia due to C. albicans, since only two of 
30 blood isolates of C.albicans in their study 
were biofilm-positive [2]. Yücesoy et al 
investigated the biofilm production of various 
Candida strains with tube adherence method and 
compared this activity with fluconazole and 
amphotericin B susceptibility. They found no 
statistically significant difference between biofilm 
activity and susceptibility to amphotericin B. 
However, statistically significant difference was 
found between biofilm activity and susceptibility 
to fluconazole (p = 0.03) [9]. These divergent 




Candida spp. isolated from various clinical 
samples were highly susceptible to the tested 
antifungals, namely, fluconazole and 
voriconazole. Since voriconazole exhibits higher 
efficacy than fluconazole in non-C. albicans 
isolates it may be appropriate to prefer 
voriconazole in the treatment of fungal infections 
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